Cargando…
Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with huma...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228553/ https://www.ncbi.nlm.nih.gov/pubmed/28105352 http://dx.doi.org/10.3892/mco.2016.1058 |
_version_ | 1782493969165320192 |
---|---|
author | Kondo, Tomohiro Kitayama, Hiromitsu Sugiyama, Junko Hirayama, Michiaki Suzuki, Yoshinori Oyamada, Yumiko Tsuji, Yasushi |
author_facet | Kondo, Tomohiro Kitayama, Hiromitsu Sugiyama, Junko Hirayama, Michiaki Suzuki, Yoshinori Oyamada, Yumiko Tsuji, Yasushi |
author_sort | Kondo, Tomohiro |
collection | PubMed |
description | Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with human epidermal growth factor receptor 2-positive gastric cancer with peritoneal, pulmonary and bilateral ovarian metastases. After 6 cycles of S-1 plus cisplatin with trastuzumab, followed by 15 cycles of intravenous and intraperitoneal paclitaxel with S-1 and trastuzumab, the pulmonary and peritoneal metastases exhibited complete response and no evidence of malignancy was found on diagnostic laparoscopy. We performed metastasectomy of the bilateral sizeable ovaries, followed by total gastrectomy. The patient had no recurrence for 16 months after the gastrectomy. Therefore, satisfactory response to systemic and intraperitoneal chemotherapy may convert unresectable to resectable disease, and primary tumor resection with ovarian metastasectomy may prolong survival. This combination chemotherapy has the potential of becoming a conversion therapy for gastric cancer with peritoneal metastases, even if ascites and ovarian metastases are extensive. |
format | Online Article Text |
id | pubmed-5228553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-52285532017-01-19 Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy Kondo, Tomohiro Kitayama, Hiromitsu Sugiyama, Junko Hirayama, Michiaki Suzuki, Yoshinori Oyamada, Yumiko Tsuji, Yasushi Mol Clin Oncol Articles Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with human epidermal growth factor receptor 2-positive gastric cancer with peritoneal, pulmonary and bilateral ovarian metastases. After 6 cycles of S-1 plus cisplatin with trastuzumab, followed by 15 cycles of intravenous and intraperitoneal paclitaxel with S-1 and trastuzumab, the pulmonary and peritoneal metastases exhibited complete response and no evidence of malignancy was found on diagnostic laparoscopy. We performed metastasectomy of the bilateral sizeable ovaries, followed by total gastrectomy. The patient had no recurrence for 16 months after the gastrectomy. Therefore, satisfactory response to systemic and intraperitoneal chemotherapy may convert unresectable to resectable disease, and primary tumor resection with ovarian metastasectomy may prolong survival. This combination chemotherapy has the potential of becoming a conversion therapy for gastric cancer with peritoneal metastases, even if ascites and ovarian metastases are extensive. D.A. Spandidos 2016-12 2016-10-21 /pmc/articles/PMC5228553/ /pubmed/28105352 http://dx.doi.org/10.3892/mco.2016.1058 Text en Copyright: © Kondo et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Kondo, Tomohiro Kitayama, Hiromitsu Sugiyama, Junko Hirayama, Michiaki Suzuki, Yoshinori Oyamada, Yumiko Tsuji, Yasushi Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title_full | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title_fullStr | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title_full_unstemmed | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title_short | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
title_sort | conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228553/ https://www.ncbi.nlm.nih.gov/pubmed/28105352 http://dx.doi.org/10.3892/mco.2016.1058 |
work_keys_str_mv | AT kondotomohiro conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT kitayamahiromitsu conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT sugiyamajunko conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT hirayamamichiaki conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT suzukiyoshinori conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT oyamadayumiko conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy AT tsujiyasushi conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy |